Lilly Endowment Inc Sells 220,000 Shares of Eli Lilly and Company (NYSE:LLY) Stock
Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the completion of the transaction, the insider now directly owns 111,003,815 shares of the company’s stock, valued at $20,590,097,644.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of NYSE:LLY opened at $185.50 on Thursday. The company has a 50 day moving average of $161.85 and a 200-day moving average of $153.50. The firm has a market cap of $177.45 billion, a P/E ratio of 30.31, a P/E/G ratio of 1.52 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $117.06 and a twelve month high of $189.30. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Sunday, November 1st. The company reported $1.54 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.17). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.87 billion. During the same period in the prior year, the company posted $1.48 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 7.21 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Nuveen Asset Management LLC raised its holdings in shares of Eli Lilly and by 42.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 8,026,867 shares of the company’s stock worth $1,317,851,000 after purchasing an additional 2,372,251 shares in the last quarter. FMR LLC raised its holdings in shares of Eli Lilly and by 7.0% in the 2nd quarter. FMR LLC now owns 29,992,097 shares of the company’s stock worth $4,924,101,000 after purchasing an additional 1,954,811 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Eli Lilly and in the 3rd quarter worth approximately $194,874,000. Two Sigma Advisers LP raised its holdings in shares of Eli Lilly and by 72.3% in the 2nd quarter. Two Sigma Advisers LP now owns 2,390,116 shares of the company’s stock worth $392,409,000 after purchasing an additional 1,003,200 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Eli Lilly and by 41.4% in the 3rd quarter. First Trust Advisors LP now owns 1,565,700 shares of the company’s stock worth $231,755,000 after purchasing an additional 458,790 shares in the last quarter. Institutional investors and hedge funds own 69.85% of the company’s stock.
Several research analysts have recently commented on LLY shares. Mizuho lifted their price target on shares of Eli Lilly and from $156.00 to $164.00 and gave the company a “neutral” rating in a report on Wednesday, December 16th. BidaskClub raised shares of Eli Lilly and from a “strong sell” rating to a “sell” rating in a research note on Friday, December 11th. Morgan Stanley reduced their target price on shares of Eli Lilly and from $176.00 to $170.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Truist boosted their target price on shares of Eli Lilly and from $182.00 to $200.00 in a research note on Tuesday. Finally, Wolfe Research raised shares of Eli Lilly and from a “peer perform” rating to an “outperform” rating and boosted their target price for the company from $147.00 to $183.00 in a research note on Thursday, December 10th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $171.13.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Further Reading: What is Liquidity?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.